{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:52:34Z","timestamp":1776477154518,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Orchidia Pharmaceutical Industry"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03411-x","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:23:22Z","timestamp":1737350602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide\/timolol) in ocular hypertension and\/or glaucoma"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-9615","authenticated-orcid":false,"given":"Sihem","family":"Lazreg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7663-5043","authenticated-orcid":false,"given":"Ahmed Hassan","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-2924","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-0224","authenticated-orcid":false,"given":"Mohamed","family":"Hosny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Shafik","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat Mohamed","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-9683","authenticated-orcid":false,"given":"Tamer Mohamed","family":"El-Raggal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-6049","authenticated-orcid":false,"given":"Waleed Ali Moustafa","family":"Abou Samra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-1543","authenticated-orcid":false,"given":"Yehia Salah Eldin","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"3411_CR1","doi-asserted-by":"publisher","unstructured":"Kulkarni S, Damji, Buys (2008) Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. Patient Prefer Adherence 303. https:\/\/doi.org\/10.2147\/PPA.S4163","DOI":"10.2147\/PPA.S4163"},{"key":"3411_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/bjo.80.5.389","volume":"80","author":"HA Quigley","year":"1996","unstructured":"Quigley HA (1996) Number of people with glaucoma worldwide. Br J Ophthalmol 80:389\u2013393. https:\/\/doi.org\/10.1136\/bjo.80.5.389","journal-title":"Br J Ophthalmol"},{"key":"3411_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0225","author":"AK Schuster","year":"2020","unstructured":"Schuster AK, Erb C, Hoffmann EM et al (2020) The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.2020.0225","journal-title":"Dtsch Arztebl Int"},{"key":"3411_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41433-019-0633-6","volume":"34","author":"A Garg","year":"2020","unstructured":"Garg A, Gazzard G (2020) Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. Eye 34:60\u201371. https:\/\/doi.org\/10.1038\/s41433-019-0633-6","journal-title":"Eye"},{"key":"3411_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0039-6257(79)90125-5","volume":"24","author":"FM Wilson","year":"1979","unstructured":"Wilson FM (1979) Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol 24:57\u201388. https:\/\/doi.org\/10.1016\/0039-6257(79)90125-5","journal-title":"Surv Ophthalmol"},{"key":"3411_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/bjo.80.7.583","volume":"80","author":"LA Wilson","year":"1996","unstructured":"Wilson LA (1996) To preserve or not to preserve, is that the question? Br J Ophthalmol 80:583\u2013584. https:\/\/doi.org\/10.1136\/bjo.80.7.583","journal-title":"Br J Ophthalmol"},{"key":"3411_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/jop.2010.0060","volume":"26","author":"G Renieri","year":"2010","unstructured":"Renieri G, F\u00fchrer K, Scheithe K et al (2010) Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients. J Ocul Pharmacol Ther 26:597\u2013603. https:\/\/doi.org\/10.1089\/jop.2010.0060","journal-title":"J Ocul Pharmacol Ther"},{"key":"3411_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00417-010-1397-7","volume":"248","author":"A Shedden","year":"2010","unstructured":"Shedden A, Adamsons IA, Getson AJ et al (2010) Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination (COSOPT\u2122) in patients with elevated intraocular pressure in a randomized clinical trial. Graefe\u2019s Arch Clin Exp Ophthalmol 248:1757\u20131764. https:\/\/doi.org\/10.1007\/s00417-010-1397-7","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"3411_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","volume":"246","author":"C Erb","year":"2008","unstructured":"Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe\u2019s Arch Clin Exp Ophthalmol 246:1593\u20131601. https:\/\/doi.org\/10.1007\/s00417-008-0881-9","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"3411_CR10","unstructured":"Pharmaceuticals O Twinzol-SDU. https:\/\/orchidiapharma.com\/en\/Products\/Anti-infective_eye_drops\/News\/SDU__Single_Dose_Unit_. Accessed 17 Dec 2024"},{"key":"3411_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/eye.2009.300","volume":"24","author":"L Quaranta","year":"2010","unstructured":"Quaranta L, Konstas AGP, Rossetti L et al (2010) Untreated 24-h intraocular pressures measured with Goldmann applanation tonometry vs nighttime supine pressures with Perkins applanation tonometry. Eye 24:1252\u20131258. https:\/\/doi.org\/10.1038\/eye.2009.300","journal-title":"Eye"},{"key":"3411_CR12","unstructured":"PHYSICIAN GLOBAL ASSESSMENT (PGA). https:\/\/assesschild.com\/physician-global-assessment"},{"key":"3411_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/00006324-200206000-00009","volume":"79","author":"JJ Nichols","year":"2002","unstructured":"Nichols JJ, Nichols KK, Puent B et al (2002) Evaluation of tear film interference patterns and measures of tear break-up time. Optom Vis Sci 79:363\u2013369. https:\/\/doi.org\/10.1097\/00006324-200206000-00009","journal-title":"Optom Vis Sci"},{"key":"3411_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3341\/kjo.1988.2.2.69","volume":"2","author":"JH Lee","year":"1988","unstructured":"Lee JH, Kee CW (1988) The significance of tear film break-up time in the diagnosis of dry eye syndrome. Korean J Ophthalmol 2:69. https:\/\/doi.org\/10.3341\/kjo.1988.2.2.69","journal-title":"Korean J Ophthalmol"},{"key":"3411_CR15","unstructured":"J. W (2004) Ocular Surface Disease Index (OSDI) Administration and Scoring Manual. Irvine, CA Allergan, Inc2004. Allergen"},{"key":"3411_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM (2000) Reliability and Validity of the Ocular Surface Disease Index. Arch Ophthalmol 118:615. https:\/\/doi.org\/10.1001\/archopht.118.5.615","journal-title":"Arch Ophthalmol"},{"key":"3411_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/ICO.0b013e31823f8cb6","volume":"31","author":"A Labb\u00e9","year":"2012","unstructured":"Labb\u00e9 A, Terry O, Brasnu E et al (2012) Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension. Cornea 31:994\u2013999. https:\/\/doi.org\/10.1097\/ICO.0b013e31823f8cb6","journal-title":"Cornea"},{"key":"3411_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H et al (2010) Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res 29:312\u2013334. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.03.001","journal-title":"Prog Retin Eye Res"},{"key":"3411_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3341\/kjo.2021.0010","volume":"35","author":"HJ Seong","year":"2021","unstructured":"Seong HJ, Lee K, Lee SJ et al (2021) Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma. Korean J Ophthalmol 35:235\u2013241. https:\/\/doi.org\/10.3341\/kjo.2021.0010","journal-title":"Korean J Ophthalmol"},{"key":"3411_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/603782","volume":"2013","author":"M Tomi\u0107","year":"2013","unstructured":"Tomi\u0107 M, Ka\u0161telan S, Mete\u017e Soldo K, Salopek-Rabati\u0107 J (2013) Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma. Biomed Res Int 2013:1\u20137. https:\/\/doi.org\/10.1155\/2013\/603782","journal-title":"Biomed Res Int"},{"key":"3411_CR21","first-page":"2","volume":"59","author":"MC Coroi","year":"2015","unstructured":"Coroi MC, Bungau S, Tit M (2015) PRESERVATIVES FROM THE EYE DROPS AND THE OCULAR SURFACE. Rom J Ophthalmol 59:2\u20135","journal-title":"Rom J Ophthalmol"},{"key":"3411_CR22","doi-asserted-by":"publisher","unstructured":"Ashton, P., Podder, S.K. & Lee VH. (1991) Formulation Influence on Conjunctival Penetration of Four Beta Blockers in the Pigmented Rabbit: A Comparison with Corneal Penetration. Pharm Res 8, 1166\u20131174 (1991). Pharm Res Springer Link. https:\/\/doi.org\/10.1023\/A:1015810619869","DOI":"10.1023\/A:1015810619869"},{"key":"3411_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000192082","volume":"41","author":"P Pellinen","year":"2009","unstructured":"Pellinen P, Lokkila J (2009) Corneal Penetration into Rabbit Aqueous Humor Is Comparable between Preserved and Preservative-Free Tafluprost. Ophthalmic Res 41:118\u2013122. https:\/\/doi.org\/10.1159\/000192082","journal-title":"Ophthalmic Res"},{"key":"3411_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1120672118785280","volume":"29","author":"M Misiuk-Hojlo","year":"2019","unstructured":"Misiuk-Hojlo M, Pomorska M, Mulak M et al (2019) The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol 29:210\u2013215. https:\/\/doi.org\/10.1177\/1120672118785280","journal-title":"Eur J Ophthalmol"},{"key":"3411_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","volume":"23","author":"R Batra","year":"2014","unstructured":"Batra R, Tailor R, Mohamed S (2014) Ocular Surface Disease Exacerbated Glaucoma. J Glaucoma 23:56\u201360. https:\/\/doi.org\/10.1097\/IJG.0b013e318264cd68","journal-title":"J Glaucoma"},{"key":"3411_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/ph15020201","volume":"15","author":"S-W Park","year":"2022","unstructured":"Park S-W, Lee J, Kook M (2022) Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide\/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease. Pharmaceuticals 15:201. https:\/\/doi.org\/10.3390\/ph15020201","journal-title":"Pharmaceuticals"},{"key":"3411_CR27","doi-asserted-by":"publisher","unstructured":"Uusitalo H, Egorov E, Kaarniranta K, et al (2016) Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol 445. https:\/\/doi.org\/10.2147\/OPTH.S91402","DOI":"10.2147\/OPTH.S91402"},{"key":"3411_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"RD Fechtner","year":"2010","unstructured":"Fechtner RD, Godfrey DG, Budenz D et al (2010) Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications. Cornea 29:618\u2013621. https:\/\/doi.org\/10.1097\/ICO.0b013e3181c325b2","journal-title":"Cornea"},{"key":"3411_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.5301\/ejo.5000977","volume":"27","author":"F P\u00e9rez-Bartolom\u00e9","year":"2017","unstructured":"P\u00e9rez-Bartolom\u00e9 F, Mart\u00ednez-de-la-Casa JM, Arriola-Villalobos P et al (2017) Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. Eur J Ophthalmol 27:694\u2013704. https:\/\/doi.org\/10.5301\/ejo.5000977","journal-title":"Eur J Ophthalmol"},{"key":"3411_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000356468","volume":"231","author":"L Abeg\u00e3o Pinto","year":"2014","unstructured":"Abeg\u00e3o Pinto L, Vandewalle E, Gerlier L, Stalmans I (2014) Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol\/Dorzolamide Fixed Combination. Ophthalmologica 231:166\u2013171. https:\/\/doi.org\/10.1159\/000356468","journal-title":"Ophthalmologica"},{"key":"3411_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/bjo.77.9.590","volume":"77","author":"D Broadway","year":"1993","unstructured":"Broadway D, Grierson I, Hitchings R (1993) Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 77:590\u2013596. https:\/\/doi.org\/10.1136\/bjo.77.9.590","journal-title":"Br J Ophthalmol"},{"key":"3411_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.optom.2016.11.002","volume":"10","author":"M Safarzadeh","year":"2017","unstructured":"Safarzadeh M, Azizzadeh P, Akbarshahi P (2017) Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. J Optom 10:258\u2013264. https:\/\/doi.org\/10.1016\/j.optom.2016.11.002","journal-title":"J Optom"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03411-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:02:27Z","timestamp":1766167347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03411-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3411"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03411-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and its investigators were fully sponsored and funded by Orchidia Pharmaceutical Industry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and its amendments were submitted to independent ethics committees (IECs) of \"Genuine Research Center (GRC)\" under study code \"GRC\/ORCDT\/EG\/37\/CT\", protocol code number \"ORC-001\" for review and written approval. It complied with recommendations of the 18th World Health Congress (Helsinki, 1964), laws and regulations, and any applicable guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"30"}}